Besides the identification of IGFBP5 as a potential biomarker for ASCL1High SCLC, and its role as a mediator of its adaptive response to bromodomain inhibitors, we expect that the datasets contain many previously unrecognized secreted targets of ASCL1 and NEUROD1 that will serve as an invaluable resource for future biomarker discovery, as well as for hypothesis-driven research that helps dissect the complex molecular underpinnings that drive the oncogenesis of pulmonary NE tumors. This evidence concerns the gene ASCL1 and small cell lung carcinoma.